1 / 6

China Patient Support Program Market Analysis - Insights10

In 2022, the market was valued at $3.89 Bn, and itu2019s set to soar to an impressive $15.71 Bn by 2030, with a remarkable CAGR of 19.1%. This rapid growth highlights the increasing importance of patient-centric care and support programs in the Chinese healthcare landscape. Join the conversation and see how these industry giants are shaping the future of patient care in China!

Insights10
Download Presentation

China Patient Support Program Market Analysis - Insights10

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHINA PATIENT SUPPORT PROGRAM

  2. HOW PSPs IN CHINA WORK? Pharmaceutical Companies Charitable Organization Patients Under Article 20 of the "Measures for the Supervision and Administration of Drug Circulation," pharmaceutical companies are prohibited from engaging in bundled sales or giving away prescription and Class A OTC drugs Therefore, to support Patient Support Programs (PSPs) by providing free drugs and funds, these companies must partner with recognized charities, making these charities crucial to the operation of PSPs Charitable organizations are central to PSPs, ensuring effective aid through several key roles: Program Management: Designing, planning, and operating PSPs. Fundraising and Advocacy: Securing donations and promoting PSPs for public and governmental support Patient Support: Assessing eligibility, educating the public, coordinating with healthcare providers, and ensuring safe medication distribution PSPs by charitable organizations provide vital support for patients with serious illnesses through various models: Co-assistance Model: Patients initially pay for a treatment cycle and then receive subsequent cycles free. Full Free Model: Patients receive drugs at no cost without any self- payment or treatment requirements Financial Assistance Model: Offers cash rebates based on drug purchase invoices to help cover treatment expenses

  3. 20 China Patient Support Program Market Forecast, 2022-2030F (in $Bn) 15.71 MARKET SIZE & FORECAST 15 CAGR-19.1% 13.19 11.08 China Patient Support Program Market Analysis in 2022 was sized at $3.89 Bn and is projected to reach $15.71 Bn by 2030, exhibiting a CAGR of 19.1% during the forecast period 10 9.3 7.81 6.56 5.51 4.63 5 3.89 0 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F

  4. TOP PLAYERS IN CHINA Top Pharma Companies Top Charitable Organizations

  5. MARKET SEGMENTATION BY TYPE BY DISEASE BY CITIES 1. 2. Drug assistance Financial assistance 1. 2. 3. 4. 5. Tumors Rare disease Chronic disease Autoimmune disease Other 1. 2. 3. 4. 5. 6. First tier cities New first tier cities Second tier cities Third tier cities Fourth tier cities Fifth tier cities 2022 In, 82% the various types of program drug assistance programs accounted for of all PSPs, marking the highest proportion among

  6. MARKET DRIVER & RESTRAINT MARKET DRIVERS: MARKET RESTRAINTS: An aging population creates a booming demand for PSPs Lack of awareness about the disease & PSPs challenges their adoption in China Lack of standardization hinders patient choice in China's booming PSPs market Digital health adoption in China creates opportunities for PSPs High support from the government and increasing donations drive growth

More Related